Company intelligence / Profile preview

Gene Tools

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Gene Tools provides custom Morpholino antisense oligos widely used in academic and industry labs for gene knockdown, splice modification, miRNA inhibition, and related applications. Their products support target validation and mechanistic studies but are not themselves clinical candidates. The underlying Morpholino chemistry has enabled several FDA-approved drugs developed by other companies.

Therapeutic areas: Rare Diseases
Modalities: Antisense oligonucleotide
Industry: Non-Drug Biotech

Partnerships

Funakoshi Co. (exclusive distributor in Japan)Sarepta Therapeutics/AVI Biopharma/Antivirals Inc.: historical connection as spin-off but no current ownership relationship

Beyond the preview

Go deeper on Gene Tools.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gene Tools.

Explore the full profile